Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06DET
|
||||
| Former ID |
DNC000164
|
||||
| Drug Name |
AE-3763
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] | Discontinued in Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H35N3O3
|
||||
| Canonical SMILES |
CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C.C1CCC(CC1)(CC(=O)O)CN
|
||||
| InChI |
1S/C14H18N2O.C9H17NO2/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13;10-7-9(6-8(11)12)4-2-1-3-5-9/h5-10H,1-4H3;1-7,10H2,(H,11,12)
|
||||
| InChIKey |
GTYTZCYUQFEJFM-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 50847-11-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
R03DC04
|
||||
| SuperDrug CAS ID |
cas=050847115
|
||||
| Target and Pathway | |||||
| Target(s) | Leukocyte elastase | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Transcriptional misregulation in cancer | ||||
| Systemic lupus erythematosus | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| C-MYB transcription factor network | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Human Complement System | |||||
| Degradation of collagen | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015539) | ||||
| REF 2 | Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.